Source: Annual Congress 2010 - Pathogenesis of diffuse parenchymal lung disease
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
P. Kopinski, K. Szablowska, G. Przybylski, A. Jarzemska, G. Pinis, B. Balicka-Slusarczyk, A. Szlubowski, J. Szczeklik (Bydgoszcz, Krakow, Poland). Enhanced apoptosis of alveolar lymphocytes (AL), but not macrophages (AM) in interstitial idiopathic pneumonias (IIPs). Special attention to idiopathic pulmonary fibrosis (IPF) results. Eur Respir J 2010; 36: Suppl. 54, 4179

Member's Comments

No comment yet.

Related content which might interest you: Alveolar lymphocytes (AL) apoptosis in interstitial lung diseases (ILD). Increased AL apoptosis rate in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2009 - Pathogenesis of pulmonary fibrosis Year: 2009 Elevated apoptosis rate of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonitis (NSIP) – strong positive correlation with bronchoalvoelar lavage (BAL) neutrophil count. Source: Virtual Congress 2020 – Translational aspects of idiopathic pulmonary fibrosis Year: 2020 Cykine/receptor inflammatory profile in different types of idiopathic intestitial pneumonias (IIPs). Key role of Fas Ligand recruvation in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2010 - Biomarkers in diffuse parenchymal lung disease Year: 2010 Increased apoptosis of alveolar lymphocytes (AL) in idiopathic pulmonary fibrosis (IPF). Potential mechanisms and practical considerations Source: Annual Congress 2013 –Idiopathic pulmonary fibrosis: clinical view Year: 2013 Inhibition of local fibrinolysis differs between idiopathic pulmonary fibrosis (IPF) and fibrotic non-specific interstitial pneumonia (f-NSIP) Source: Annual Congress 2009 - Idiopathic pulmonary fibrosis: concepts and mechanisms Year: 2009 Clinical and functional features in idiopathic pulmonary fibrosis (IPF) with and without haemosiderin-laden alveolar macrophages on BALF Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011 Comparative proteome analysis of lung tissue from patients with idiopathic pulmonary fibrosis (IPF) and non-specific interstitial pneumonia (NSIP) Source: Annual Congress 2013 –Connective tissue disease and interstitial lung disease Year: 2013 Cytokines, chemokines and growth factors concentration in BAL fluid from patients with Idiopathic pulmonary fibrosis (IPF) and nonspecific interstitial pneumonia (NSIP) Source: Virtual Congress 2020 – Prognosis and biomarkers of idiopathic pulmonary fibrosis Year: 2020 Idiopathic pulmonary fibrosis (IPF) and idiopathic nonspecific interstitial pneumonia (NSIP): what treatment and for whom? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006 Aerosolized interferon-gamma (IFN-γ) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2007 - Considerations in the therapeutic approach of interstitial lung disease: oxidative stress and inflammation Year: 2007 Contribute of BAL proteomic analysis in sarcoidosis (S) and in idiopathic pulmonary fibrosis (IPF/UIP) Source: Eur Respir J 2006; 28: Suppl. 50, 564s Year: 2006 Serum surfactant protein D (SP-D) and annual decline of diffusion capacity are prognostic factors for combined pulmonary fibrosis with emphysema (CPFE) in idiopathic pulmonary fibrosis (IPF) Source: Annual Congress 2013 –Clinical respiratory physiology in different diseases Year: 2013 Histology and pathogenesis of usual interstitial pneumonia (UIP) versus nonspecific interstitial pneumonia (NSIP): progressive remodeling or resolution and healing? Source: Annual Congress 2006 - Usual interstitial pneumonia (UIP) and nonspecific interstitial pneumonia (NSIP), idiopathic or not: new concepts in diagnosis and treatment Year: 2006 Non-IPF idiopathic interstitial pneumonia (IIPs) Source: ERS Course 2016 Year: 2016 Difference in immunological aspects of inflammation in idiopathic pulmonary fibrosis (IPF) and exogenous toxic alveolitis (ETA) Source: Eur Respir J 2003; 22: Suppl. 45, 121s Year: 2003 Lysozyme level and activity are decreased in the lungs of patients with idiopathic pulmonary fibrosis (IPF) and potentially contribute to increased susceptibility to pulmonary infection Source: Annual Congress 2006 - Usefulness of broncoalveolar lavage (BAL) in interstitial lung diseases Year: 2006 Small airways structural alterations in usual interstitial pneumonia (UIP), non-specific interstitial pneumonia (NSIP), hypersensitivity pneumonia (HP) and chronic bronchiolitis (CB) Source: Eur Respir J 2006; 28: Suppl. 50, 308s Year: 2006 Treatment of idiopathic pulmonary fibrosis (IPF) with pentoxifylline (POF) Source: Eur Respir J 2007; 30: Suppl. 51, 121s Year: 2007 Idiopathic pulmonary fibrosis - IPF Source: Respipedia Article Year: 2018